- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07715877
Social Media Connectedness in Fibromyalgia
Connectedness Via Social Media in Fibromyalgia Patients
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Fibromyalgia is a chronically complex disease of unknown etiology defined by extensive vague musculoskeletal pain, modestly effective treatments, and strong association with psychiatric disorders such as depression and anxiety. Due to the nebulousness of fibromyalgia that engenders stigma and invalidation, psychiatrically related symptoms of hopelessness and loneliness are prevalent among patients suffering from it. These symptoms in turn can worsen outcomes and make this population vulnerable to suicidal ideation. Social support has been shown to improve physical and mental well-being in patients with fibromyalgia. Given that the primary purpose of social media is to promote social support, there has been increasing interest in harnessing social media as a therapeutic intervention. However, evidence for the therapeutic benefit of social media, particularly for loneliness mitigation and suicide prevention, is mixed. In the limited literature about fibromyalgia patients specifically, use of existing social media networks, such as Facebook and Instagram, has been shown to improve pain and depressive symptoms. The benefit of social media appears to derive from a sense of connectedness via (1) developing a sense of community among individuals with common experiences and (2) exchanging experiences, information, and support. Given the lack of research around the use of social media in fibromyalgia patients, this study aims to investigate whether social media tailored to fibromyalgia patients can improve physical and mental health. Specifically, participants were randomized to conditions of differing social media engagement (i.e. passively consuming information [TAU] vs. receiving specific user-generated content evaluated to be validating and supportive [e-TAU] vs. receiving this helpful content while participating in a support group [e-TAU+G]) to delineate how different aspects social media use contribute to connectedness and improved outcomes. This study is needed, as fibromyalgia patients are a group that would benefit most from an easily accessible and affordable modality that can bolster social support.
This study constitutes analysis of data collected by themighty.com. Themighty.com is a social media platform dedicated to promoting health and well-being. The platform features stories reflecting lived experience with physical and mental health challenges. In addition, themighty.com offers a peer-to-peer forum for users to solicit and receive support. From January to October 2023, themighty.com collected data to evaluate users' engagement with and benefits of their platform. The study collected data using a randomized control design (three arms) over an 18-week period before crossover. Participants were randomized using simple randomization. Condition assignment was not blinded. However, a cross-over strategy was employed, wherein participants originally assigned to the TAU condition were then allocated to the e-TAU+G condition after the initial 18-week trial.
This study's hypothesis is that the e-TAU+G arm would show greatest improvements in outcomes, followed by the e-TAU arm, with the TAU arm showing the least improvement.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
New York
-
The Bronx, New York, Forenede Stater, 10461
- Albert Einstein College of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- 18 years of age or older
- Can read and write English proficiently
- Live in the USA
- Carry a diagnosis of fibromyalgia
Exclusion Criteria:
- Younger than 18-years-old
- Cannot read or write English proficiently
- Does not live in the U.S.
- Does not carry fibromyalgia diagnosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Treatment as usual (TAU)
Participants used the platform as usual (e.g., log in, read stories).
|
Participants were invited to join a closed group to facilitate discussion about their experiences with fibromyalgia and offer social support.
|
|
Enhanced TAU (e-TAU)
Participants received specialized emails from the platform containing user-generated stories featuring lived experience with fibromyalgia that were identified as helpful for increasing social connectedness/support and hope, in addition to typical platform use.
|
Participants were invited to join a closed group to facilitate discussion about their experiences with fibromyalgia and offer social support.
|
|
Enhanced TAU + group (e-TAU+G)
In addition to receiving the specialized emails with supportive narratives, participants were invited to join a closed group of other people with fibromyalgia that would facilitate communication amongst members.
|
Participants were invited to join a closed group to facilitate discussion about their experiences with fibromyalgia and offer social support.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Perceived Shared Experiences
Tidsramme: Weeks 6, 12, and 18
|
Perceived shared experiences were assessed via online survey by asking participants the question, "In the past week, how much did you feel like you are not the only person living with your struggles?"
Participants provided responses using a 7-item Likert scale ranging from 1 ("Definitely not the only one") to 7 ("Completely the only one"), such that lower scores were indicative of an increased sense of shared experiences and higher scores were indicative of a decreased sense of shared experiences.
This survey was administered weekly during the trial.
|
Weeks 6, 12, and 18
|
|
Hopefulness/Hopelessness
Tidsramme: Weeks 6, 12, and 18
|
Hopefulness and hopelessness were assessed via online survey by asking participants the question, "In the past week, how much do you feel like the problems you are currently facing might get better in the future?"
Participants provided responses using a 7-item Likert scale ranging from 1 ("Not at all") to 7 ("Definitely"), such that higher scores were indicative of increased feelings of hopefulness and lower scores were indicative of increased feelings of hopelessness.
This survey was administered weekly during the trial.
|
Weeks 6, 12, and 18
|
|
Validation and Understanding
Tidsramme: Weeks 6, 12, and 18
|
Validation and feelings of being understood were assessed via online survey by asking participants the question, "In the past week, how understood did you feel by others?"
Participants provided responses using a 7-item Likert scale ranging from 1 ("Not at all understood") to 7 ("Definitely understood"), such that higher scores were indicative of increased feelings of validation and understanding and lower scores were indicative of decreased feelings of validation and understanding.
This survey was administered weekly during the trial.
|
Weeks 6, 12, and 18
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Suicidal Ideation
Tidsramme: Weeks 6, 12, and 18
|
Suicidal ideation was assessed via online survey by asking participants the question, "In the past week, how often did you have thoughts of not wanting to be alive or of hurting yourself in some way?" Participants provided responses using a 7-item Likert scale ranging from 1 ("I didn't have these thoughts at all") to 7 ("Every day"), such that higher scores were indicative of increased thoughts of suicidal ideation and lower scores were indicative of decreased thoughts of suicidal ideation.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Weeks 6, 12, and 18
|
|
Depression
Tidsramme: Weeks 6, 12, and 18
|
Depression was assessed using the 9-item Patient Health Questionnaire (PHQ-9).
The PHQ-9 is a standard measurement tool used for screening, diagnosing, monitoring and measuring the severity of depression.
Participants were asked how often they had been bothered by symptoms like depressed mood, trouble sleeping, or low energy over the past two weeks.
Each question is scored on a 4-point scale ranging from 0 ("Not at all") to 3 ("Nearly every day"), for an overall possible scoring range of 0-27, such that higher scores were indicative of increased depressive symptoms.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Weeks 6, 12, and 18
|
|
Anxiety
Tidsramme: Weeks 6, 12, and 18
|
Anxiety was assessed using the 7-item Generalized Anxiety Disorder-7 (GAD-7) scale.
The GAD-7 is a self-assessment tool used to screen for and asses the severity of anxiety.
Participants were asked how often they had been bothered by common symptoms of anxiety over the prior two week period.
Each question is scored on a 4-point scale ranging from 0 ("Not at all") to 3 ("Nearly every day"), for an overall possible scoring range of 0-21, such that higher scores were indicative of increased anxiety symptoms.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Weeks 6, 12, and 18
|
|
Functional Impairment
Tidsramme: Weeks 6, 12, and 18
|
Functional impairment was assessed via online survey by asking participants the question, "In the past week, how often did your fibromyalgia symptoms get in the way of your goals?"
Participants provided responses using a 7-item Likert scale ranging from 1 ("Not at all") to 7 ("Every day"), such that higher scores were indicative of increased functional impairment and lower scores were indicative of decreased functional impairment.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Weeks 6, 12, and 18
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Perceived Burdensomeness and Thwarted Belongingness
Tidsramme: Administered weeks 6, 12, and 18
|
Perceived burdensomeness and Thwarted belongingness were assessed using the 15-item Interpersonal Needs Questionnaire (INQ-15).
The INQ-15 is a widely used clinical assessment tool designed to evaluate two psychological constructs linked to suicide ideation: perceived burden and thwarted belonging.
Perceived burdensomeness subscale items (questions 1-6) were rated on a scale ranging from 1 ("Not at all true") to 7 ("Very true"), yielding a range of 6-42.
Thwarted belongingness subscale items (questions 7-15) were rated on a scale ranging from 1 ("Not at all true") to 7 ("Very true"), yielding a range of 9-63.
A total perceive burden score was calculated by combining the two subscales, yielding an overall scoring range of 15-99, such that higher scores are indicative of increased perceived burden and thwarted belonging.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Administered weeks 6, 12, and 18
|
|
Post-Traumatic Stress Disorder (PTSD)
Tidsramme: Administered weeks 6, 12, and 18.
|
PTSD was assessed using the Short PTSD Rating Interview (SPRINT).
SPRINT is an 8-item clinical assessment tool designed to quickly evaluate the core symptoms and severity of PTSD (intrusion, avoidance, numbing, arousal) along with somatic malaise, stress vulnerability, and role and social functional impairment.
Participants provide responses to each of the 8 items based on their experiences over the past week using a 5-point scale ranging from 0 ("Not at all") to 4 ("Very much"), for an overall possible score of 0-32, such that higher scores are indicative of increased severity of PTSD symptoms.
Milestone surveys were administered at weeks 6, 12, and 18. Scores were summarized by study arm.
|
Administered weeks 6, 12, and 18.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Peter Franz, PhD, Albert Einstein College of Medicine
Publikationer og nyttige links
Generelle publikationer
- Kleykamp BA, Ferguson MC, McNicol E, Bixho I, Arnold LM, Edwards RR, Fillingim R, Grol-Prokopczyk H, Turk DC, Dworkin RH. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum. 2021 Feb;51(1):166-174. doi: 10.1016/j.semarthrit.2020.10.006. Epub 2020 Dec 29.
- Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE 3rd, Bekaii-Saab T, Martin EW Jr, Schmidt CR, Kiecolt-Glaser JK. Pain, depression, and fatigue: loneliness as a longitudinal risk factor. Health Psychol. 2014 Sep;33(9):948-57. doi: 10.1037/a0034012. Epub 2013 Aug 19.
- Loge-Hagen JS, Saele A, Juhl C, Bech P, Stenager E, Mellentin AI. Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis. J Affect Disord. 2019 Feb 15;245:1098-1105. doi: 10.1016/j.jad.2018.12.001. Epub 2018 Dec 3.
- Kool MB, Geenen R. Loneliness in patients with rheumatic diseases: the significance of invalidation and lack of social support. J Psychol. 2012 Jan-Apr;146(1-2):229-41. doi: 10.1080/00223980.2011.606434.
- Ordonez-Carrasco JL, Sanchez-Castello M, Calandre EP, Cuadrado-Guirado I, Rojas-Tejada AJ. Suicidal Ideation Profiles in Patients with Fibromyalgia Using Transdiagnostic Psychological and Fibromyalgia-Associated Variables. Int J Environ Res Public Health. 2020 Dec 30;18(1):209. doi: 10.3390/ijerph18010209.
- Wolf LD, Davis MC. Loneliness, daily pain, and perceptions of interpersonal events in adults with fibromyalgia. Health Psychol. 2014 Sep;33(9):929-37. doi: 10.1037/hea0000059.
- Reig-Garcia G, Bosch-Farre C, Suner-Soler R, Juvinya-Canal D, Pla-Vila N, Noell-Boix R, Boix-Roqueta E, Mantas-Jimenez S. The Impact of a Peer Social Support Network from the Perspective of Women with Fibromyalgia: A Qualitative Study. Int J Environ Res Public Health. 2021 Dec 4;18(23):12801. doi: 10.3390/ijerph182312801.
- O'Day, E. B., & Heimberg, R. G. (2021). Social media use, social anxiety, and loneliness: A systematic review. Computers in Human Behavior Reports, 3(100070). https://doi.org/10.1016/j.chbr.2021.100070
- Robinson J, Cox G, Bailey E, Hetrick S, Rodrigues M, Fisher S, Herrman H. Social media and suicide prevention: a systematic review. Early Interv Psychiatry. 2016 Apr;10(2):103-21. doi: 10.1111/eip.12229. Epub 2015 Feb 19.
- Berard AA, Smith AP. Post Your Journey: Instagram as a Support Community for People With Fibromyalgia. Qual Health Res. 2019 Jan;29(2):237-247. doi: 10.1177/1049732318789102. Epub 2018 Aug 1.
- Pester BD, Tankha H, Cano A, Tong S, Grekin E, Bruinsma J, Gootee J, Lumley MA. Facing Pain Together: A Randomized Controlled Trial of the Effects of Facebook Support Groups on Adults With Chronic Pain. J Pain. 2022 Dec;23(12):2121-2134. doi: 10.1016/j.jpain.2022.07.013. Epub 2022 Sep 9.
- Cipolletta S, Tomaino SCM, Lo Magno E, Faccio E. Illness Experiences and Attitudes towards Medication in Online Communities for People with Fibromyalgia. Int J Environ Res Public Health. 2020 Nov 23;17(22):8683. doi: 10.3390/ijerph17228683.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Sygdomme i nervesystemet
- Muskelsygdomme
- Neuromuskulære sygdomme
- Reumatiske sygdomme
- Adfærdsmæssige symptomer
- Selvskadende adfærd
- Opførsel
- Selvmord
- Selvmordstanker
- Fibromyalgi
- Depression
- Adfærdsdiscipliner og aktiviteter
- Adfærdsvidenskab
- Sociologi
- Samfundsvidenskab
- Mediedækning
Andre undersøgelses-id-numre
- 2024-16294
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fibromyalgi (FM)
-
Fundació Institut de Recerca de l'Hospital de la...AfsluttetFibromyalgi (FM)Spanien
-
University of UtahRekruttering
-
Ionclinics & Deionic SLHospital Clínico Universitario de ValenciaRekrutteringFibromyalgi (FM)Spanien
-
Ain Shams UniversityRekruttering
-
Hospital de Clinicas de Porto AlegreRekrutteringtDCS | EEG | Duloxetin | Fibromyalgi (FM) | BDNFBrasilien
-
Instituto Neurociencia Del DolorUniversity of Alcala; Universidad San SebastiánIkke rekrutterer endnuFibromyalgi | Fibromyalgi syndrom | Fibromyalgi (FM)
-
Sultan Abdulhamid Han Training and Research Hospital...Ikke rekrutterer endnuCentral sensibilisering | Smerteopfattelse | Kvantitativ sensorisk testning | Fibromyalgi (FM) | TRYKSMERTETÆRSKEL
-
Ankara Training and Research HospitalAfsluttetFibromyalgi (FM) | Myokardiefunktion | Subklinisk ventrikulær dysfunktionTyrkiet (Türkiye)
-
Universidad Nacional Andres BelloIkke rekrutterer endnu
-
Hospital Universitari Vall d'Hebron Research InstituteIkke rekrutterer endnu
Kliniske forsøg med Social Media
-
University of MichiganAfsluttet
-
113 Suicide PreventionOrygen; MindRekrutteringMeddelelse | Sociale medier | SelvmordsforebyggelseHolland
-
University of New MexicoAfsluttetUfrivillig vandladning | Urgeinkontinens | Stressinkontinens, kvindeForenede Stater
-
University of ConnecticutNational Cancer Institute (NCI)Afsluttet
-
Istanbul Medeniyet UniversityIkke rekrutterer endnuMotiverende samtale | Metabolisk kontrol | Type 1 diabetes mellitus (T1DM)Kalkun
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)AfsluttetAstma hos børnForenede Stater
-
Milton S. Hershey Medical CenterAfsluttetAspergers lidelse | Højtfungerende autismeForenede Stater
-
The Hong Kong Polytechnic UniversityAfsluttetLivskvalitet | Mentalt helbred | DemensplejereHong Kong
-
The Policy & Research GroupDepartment of Health and Human Services; Mathematica Policy Research, Inc. og andre samarbejdspartnereRekruttering
-
Cedars-Sinai Medical CenterWalter Reed National Military Medical CenterAfsluttetSarkom | Neoplasmer | Lymfom | Lymfom, Non-Hodgkin | Leukæmi | Kræft | Brystkræft | Hoved- og halskræft | Gynækologisk kræft | Glioblastom | Myelomatose | Kolorektal cancer | Hodgkin lymfom | Lungekræft | Knoglekræft | Prostatakræft | Hjernekræft | Hudkræft | Bugspytkirtelkræft | Gastrointestinal kræft | Kræft i skjoldbruskkirtlen | Cancer MetastatiskForenede Stater